Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:agalsidase_beta
|
| gptkbp:approvalYear |
2003
|
| gptkbp:ATCCode |
gptkb:A16AB04
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:drugClass |
gptkb:enzyme
|
| gptkbp:form |
lyophilized powder for solution
|
| gptkbp:halfLife |
~100 minutes
|
| gptkbp:indication |
gptkb:lysosomal_storage_disorder
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sanofi_Genzyme
|
| gptkbp:mechanismOfAction |
gptkb:enzyme_replacement_therapy
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
Rx-only
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea vomiting headache hypertension pruritus chills rash dyspnea infusion-related reactions |
| gptkbp:storage |
2-8°C
|
| gptkbp:usedFor |
gptkb:Fabry_disease
|
| gptkbp:bfsParent |
gptkb:Genzyme
gptkb:Genzyme_(2011) |
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fabrazyme
|